What is OLANZAPINE PAMOATE used for?

OLANZAPINE PAMOATE (brand name ZYPREXA Relprevv) is a Atypical Antipsychotic indicated for the prescriber, healthcare facility, patient.

What are the most common side effects of OLANZAPINE PAMOATE?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for OLANZAPINE PAMOATE. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is OLANZAPINE PAMOATE the same as ZYPREXA Relprevv?

ZYPREXA Relprevv is a brand name for OLANZAPINE PAMOATE. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

OLANZAPINE PAMOATE

Q: How does OLANZAPINE PAMOATE work?

OLANZAPINE PAMOATE works through the following mechanism: 12.1 Mechanism of Action The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism..

Atypical Antipsychotic

Brand names: ZYPREXA Relprevv

Intramuscular

Mechanism of Action

12.1 Mechanism of Action The mechanism of action of olanzapine, in the listed indications is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.

Indications

the prescriber

healthcare facility

patient

and pharmacy must all be enrolled in the ZYPREXA RELPREVV Patient Care Program. To enroll

Contraindications

• 4 CONTRAINDICATIONS None. None.

FDA Warnings

5 WARNINGS AND PRECAUTIONS Elderly Patients with Dementia-Related Psychosis: Increased risk of death and increased incidence of cerebrovascular adverse events (e
3 ) Suicide: The possibility of a suicide attempt is inherent in schizophrenia, and close supervision of high-risk patients should accompany drug therapy
7 ) Hyperglycemia and Diabetes Mellitus: In some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients taking olanzapine
1 Post-Injection Delirium/Sedation Syndrome During premarketing clinical studies of ZYPREXA RELPREVV, adverse events that presented with signs and symptoms consistent with olanzapine overdose, in particular, sedation (including coma) and/or delirium, were reported in patients following an injection of ZYPREXA RELPREVV [see Boxed Warning and Dosage and Administration ( 2

Known Side Effects

8 documented side effects by frequency

Drug Not Working

>10%

Weight Gain

>10%

Drowsiness

1-10%

Nausea

1-10%

Fatigue

1-10%

Anxiety

1-10%

Vomiting

1-10%

Condition Worsened

0.1-1%

Community Discussions

No community discussions found for OLANZAPINE PAMOATE yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → OLANZAPINE PAMOATE openFDA label JSON → OLANZAPINE PAMOATE FAERS adverse-event reports → OLANZAPINE PAMOATE ClinicalTrials.gov → completed Phase 2+ trials of OLANZAPINE PAMOATE

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intramuscular